The combined use of antiplatelet drugs acting through different mechanisms is important in ... The new P2Y 12 antagonists, prasugrel and ticagrelor, are characterized by more potent antiplatelet ...

once its effect wears off, oral antithrombotic therapy is the mainstay of prevention. The range and mechanisms of commonly prescribed oral antithrombotic drugs in current practice are shown in figure ...

The results indicated modest superiority of ticagrelor, reinforcing the need for genotype ... activation of the NLRP3 inflammasome and IL-1/IL-6 pathways as potential mechanisms driving recurrent ...

Patients were divided based on their DAPT regimens (ticagrelor + aspirin vs ... the precise biological mechanisms underlying this relationship warrant further discussion. LRP1 is known to play a ...

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

Pediatr Crit Care Med. 2013;14(6):631-643. Future studies of the epidemiology of ARDS in children and adults will benefit from iterative improvements in definition that will facilitate capturing ...

I joined the University of Sheffield in 2002 as a Senior Clinical Lecturer in Cardiology and subsequently became Professor of Cardiology in January 2011. I am Clinical Lead for the Cardiovascular ...

EU countries have agreed on a market correction mechanism which will limit episodes of extraordinarily high gas prices in the EU and thus reduce the impact of price hikes on citizens and the economy.